Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 26Lymphoma, Non-Hodgkin 13Lymphoma, Mantle-Cell 12Lymphoma, B-Cell 11Lymphoma, B-Cell, Marginal Zone 7Hematologic Diseases 6Waldenstrom Macroglobulinemia 5Lymphoma 4Leukemia, B-Cell 4Lymphoma, Follicular 3Leukemia 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Lymphoid 2Dendritic Cell Sarcoma, Interdigitating 2Multiple Myeloma 1Hematologic Neoplasms 1Chromosome 17 deletion 1Burkitt Lymphoma 1

Interventions

pomalidomide 2Dexamethasone 2venetoclax 1pirtobrutinib 1pembrolizumab 1ibrutinib 1fludarabine phosphate 1fludarabine 1daratumumab 1acalabrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chromosome 17 deletion × pirtobrutinib × 1 year × Clear all
NCT07342478 2026-05-14

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Newave Pharmaceutical Inc

Phase 3 Recruiting
306 enrolled
LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡